title: [Therapeutic result of operation combined with large-dose of roferon-A for cutaneous malignant melanoma].
abstract: OBJECTIVE
  To observe the effects of operation with large-dose of Roferon-A for cutaneous malignant melanoma.
  
  
  METHODS
  From January 1998 to December 2005, thirty-three patients with cutaneous malignant melanoma were treated. There were 20 males and 13 females, aging 17-79 years. The disease course was 2 months to 7 years. In 33 patients, nine patients identified as clinical-stage I received singly enlarged-resection to the primary lesion and performed split-thickness skin graft dermoplasty or adjacent skin flap repair; twenty-three patients identified as clinical-stage II received enlarged-resection to the primary lesion and performed proximal lymphaden scavenge as well as received split-thickness skin graft dermoplasty; and one patient identified as clinical-stage III received palliative resection to the primary lesion. All patients received large dose of, Roferon-A after operation.
  
  
  RESULTS
  There are no recidivation in the 9 patients of clinical-stage I. There are 1 recidivation and 1 quit in all the 23 patients of clinical-stage II. One patient of clinical-stage III died after 18 months of operation.
  
  
  CONCLUSIONS
  The operation combined with large-dose of Roferon-A after operation was a more effective way to treat cutaneous malignant melanoma.
authors.affiliation: Department of Plastic and Burns Surgery, West China Hospital, Sichuan University, Chengdu Sichuan, P. R. China.
authors.forename: Yaojun
authors.initials: Y
authors.lastname: Wang
authors.forename: Ying
authors.initials: Y
authors.lastname: Cen
authors.forename: Zhengyong
authors.initials: Z
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D006801:Humans; D007273:Injections, Intramuscular; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D008875:Middle Aged; D009367:Neoplasm Staging; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D016038:Skin Transplantation; D013524:Surgical Flaps; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins